[年龄相关性黄斑变性治疗的新视角]
[New perspectives in the approach to age-related macular degeneration].
作者信息
Gallego-Pinazo R, Zapata M A
机构信息
Unidad de Mácula, Servicio de Oftalmología, Hospital Universitario y Politécnico La Fe, Valencia, España; Sociedad Española de la Retina y Vítreo, Instituto de Salud Carlos III, Madrid, España.
Servicio de Oftalmología, Hospital Universitario Vall d'Hebron, Barcelona, España; Red Temática de Investigación Cooperativa OFTARED, Instituto de Salud Carlos III, Madrid, España.
出版信息
Arch Soc Esp Oftalmol. 2015 Mar;90 Suppl 1:11-4. doi: 10.1016/S0365-6691(15)30004-6.
The approval of aflibercept for the neovascular form of age-related macular degeneration has opened up the possibility of treating patients with fewer injections, since the drug can be administered once every two months. Aflibercept can also be used as rescue therapy in patients with suboptimal response to other antiangiogenic treatments. The present study reviews the scientific evidence on aflibercept, both in treatment-naïve patients and in those with an unsatisfactory response to conventional treatments.
阿柏西普获批用于治疗新生血管性年龄相关性黄斑变性，这使得减少注射次数来治疗患者成为可能，因为这种药物每两个月给药一次。阿柏西普还可用于对其他抗血管生成治疗反应欠佳的患者的挽救治疗。本研究回顾了关于阿柏西普的科学证据，涵盖初治患者以及对传统治疗反应不佳的患者。
Zotero 插件